Biopharmaceutical research companies are conducting or have conducted more than 3,700 clinical trials of new medicines in collaboration with the state’s clinical research centers, university medical schools and hospitals (2004 to present).
Of the more than 3,700 clinical trials, more than 1,000 target the nation’s six most debilitating chronic diseases—asthma, cancer, diabetes, heart disease, mental illnesses and stroke.
“There are many perceived and practical barriers to getting patients enrolled in clinical trials. As a result, only 8% of cancer patients participate in clinical trials. It is essential for all stakeholders involved in this process to cooperate in reducing these structural, clinical and attitudinal barriers. This is the only way to advance the discovery of cures, accelerate improvements in treatment options and improve the quantity and quality of life for patients.” – Paul Westrick, Cancer survivor, volunteer and advocate